Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

BACKGROUND: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmentum study. OBJECTIVE: To assess efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Rensel, Mary, Zabeti, Aram, Mealy, Maureen A, Cimbora, Daniel, She, Dewei, Drappa, Jorn, Katz, Eliezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024030/
https://www.ncbi.nlm.nih.gov/pubmed/34595983
http://dx.doi.org/10.1177/13524585211047223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024030/
https://www.ncbi.nlm.nih.gov/pubmed/34595983
http://dx.doi.org/10.1177/13524585211047223

Ejemplares similares